Cromoglicate lisetil

Drug Profile

Cromoglicate lisetil

Alternative Names: Cromoglicate lisetil hydrochloride; Cromoglicic acid; KY-556; LP-0074; N-556

Latest Information Update: 21 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyoto Pharmaceutical Industries
  • Developer Asahi Kasei; Kyoto Pharmaceutical Industries; LEO Pharma
  • Class Antiallergics; Antiasthmatics; Antihistamines; Benzopyrans; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine release inhibitors; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Mastocytosis; Psoriasis
  • Discontinued Allergic rhinitis; Asthma; Atopic dermatitis

Most Recent Events

  • 21 Jul 2015 No recent reports of development identified - Phase-II for Mastocytosis in Germany (Topical)
  • 21 Jul 2015 No recent reports of development identified - Phase-II for Psoriasis in Germany (Topical)
  • 01 May 2013 LEO Pharma completes a phase II trial in Psoriasis in Germany (NCT01722812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top